
## CITATION REPORT List of articles citing



DOI: 10.1007/s40265-022-01720-4 Drugs, 2022, , .

Source: https://exaly.com/paper-pdf/145939159/citation-report.pdf

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.		O
2	An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC). 107815522211475		0
1	Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations. <b>2023</b> , 29,		O